|
Mar 12
|
Q4 2024 Verrica Pharmaceuticals Inc Earnings Call
|
|
Mar 12
|
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ...
|
|
Mar 11
|
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 11
|
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Mar 3
|
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
|
|
Feb 27
|
Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Feb 25
|
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
|
|
Oct 9
|
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...
|
|
Jul 29
|
3 High Insider Ownership US Stocks With Up To 52% Revenue Growth
|
|
May 9
|
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
May 8
|
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
|
|
May 6
|
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
|
|
Dec 24
|
Despite recent sales, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders remain the largest stockholders with 39% ownership
|
|
Aug 24
|
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
|
|
Aug 23
|
Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
|
|
Jul 21
|
UPDATE 2-Verrica's drug gets US nod as first treatment for a type of skin infection
|
|
Jul 21
|
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
|
|
Jul 17
|
With a 39% stake, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have a lot riding on the company
|